206 related articles for article (PubMed ID: 12381509)
1. Juvenile onset spondyloarthropathies: therapeutic aspects.
Burgos-Vargas R
Ann Rheum Dis; 2002 Dec; 61 Suppl 3(Suppl 3):iii33-9. PubMed ID: 12381509
[TBL] [Abstract][Full Text] [Related]
2. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?
Mitulescu TC; Trandafir M; Dimăncescu MG; Ciuluvică RC; Popescu V; Predețeanu D; Istrate S; Voinea LM
Rom J Ophthalmol; 2018; 62(2):114-122. PubMed ID: 30206554
[TBL] [Abstract][Full Text] [Related]
3. Juvenile spondyloarthropathies: the Chinese experience.
Huang F; Zhang J; Zhu J; Guo J; Yang C
Rheum Dis Clin North Am; 2003 Aug; 29(3):531-47. PubMed ID: 12951866
[TBL] [Abstract][Full Text] [Related]
4. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy.
Baeten D; Demetter P; Cuvelier CA; Kruithof E; Van Damme N; De Vos M; Veys EM; De Keyser F
J Pathol; 2002 Mar; 196(3):343-50. PubMed ID: 11857499
[TBL] [Abstract][Full Text] [Related]
5. Juvenile spondyloarthropathy: an important clinical lesson to remember.
Sridharan R; Ngiu CS; Shaharir SS; Said MS
BMJ Case Rep; 2015 Dec; 2015():. PubMed ID: 26677159
[TBL] [Abstract][Full Text] [Related]
6. Use of dynamic magnetic resonance imaging to detect sacroiliitis in HLA-B27 positive and negative children with juvenile arthritides.
Bollow M; Biedermann T; Kannenberg J; Paris S; Schauer-Petrowski C; Minden K; Schöntube M; Hamm B; Sieper J; Braun J
J Rheumatol; 1998 Mar; 25(3):556-64. PubMed ID: 9517781
[TBL] [Abstract][Full Text] [Related]
7. Juvenile Spondyloarthropathies.
Adrovic A; Barut K; Sahin S; Kasapcopur O
Curr Rheumatol Rep; 2016 Aug; 18(8):55. PubMed ID: 27402112
[TBL] [Abstract][Full Text] [Related]
8. A short-term follow-up of enthesitis and arthritis in the active phase of juvenile onset spondyloarthropathies.
Burgos-Vargas R; Pacheco-Tena C; Vázquez-Mellado J
Clin Exp Rheumatol; 2002; 20(5):727-31. PubMed ID: 12412210
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of human leucocyte antigen class I free heavy chains on monocytes of patients with spondyloarthritis and cells transfected with HLA-B27.
Ding J; Feng Y; Zheng ZH; Li XY; Wu ZB; Zhu P
Int J Immunogenet; 2015 Feb; 42(1):4-10. PubMed ID: 25545293
[TBL] [Abstract][Full Text] [Related]
10. Geoepidemiology: the environment and spondyloarthropathies.
Ehrenfeld M
Autoimmun Rev; 2010 Mar; 9(5):A325-9. PubMed ID: 20026258
[TBL] [Abstract][Full Text] [Related]
11. Juvenile spondyloarthropathy.
Tse SM; Laxer RM
Curr Opin Rheumatol; 2003 Jul; 15(4):374-9. PubMed ID: 12819463
[TBL] [Abstract][Full Text] [Related]
12. Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors.
Subramaniam K; Tymms K; Shadbolt B; Pavli P
Intern Med J; 2015 Nov; 45(11):1154-60. PubMed ID: 26337851
[TBL] [Abstract][Full Text] [Related]
13. The juvenile-onset spondyloarthritides.
Burgos-Vargas R
Rheum Dis Clin North Am; 2002 Aug; 28(3):531-60, vi. PubMed ID: 12380369
[TBL] [Abstract][Full Text] [Related]
14. Bacterial DNA in synovial fluid cells of patients with juvenile onset spondyloarthropathies.
Pacheco-Tena C; Alvarado De La Barrera C; López-Vidal Y; Vázquez-Mellado J; Richaud-Patin Y; Amieva RI; Llorente L; Martínez A; Zúñiga J; Cifuentes-Alvarado M; Burgos-Vargas R
Rheumatology (Oxford); 2001 Aug; 40(8):920-7. PubMed ID: 11511762
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease.
Turkcapar N; Toruner M; Soykan I; Aydintug OT; Cetinkaya H; Duzgun N; Ozden A; Duman M
Rheumatol Int; 2006 May; 26(7):663-8. PubMed ID: 16136311
[TBL] [Abstract][Full Text] [Related]
16. [Spondylarthropathies and anti-TNFalpha drugs].
Pavy S; Allanore Y; Kahan A
Rev Med Interne; 2005 Sep; 26(9):717-24. PubMed ID: 16154026
[TBL] [Abstract][Full Text] [Related]
17. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
Vandooren B; Kruithof E; Yu DT; Rihl M; Gu J; De Rycke L; Van Den Bosch F; Veys EM; De Keyser F; Baeten D
Arthritis Rheum; 2004 Sep; 50(9):2942-53. PubMed ID: 15457463
[TBL] [Abstract][Full Text] [Related]
18. HLA B27 typing in 511 children with juvenile idiopathic arthritis from India.
Srivastava R; Phatak S; Yadav A; Bajpai P; Aggarwal A
Rheumatol Int; 2016 Oct; 36(10):1407-11. PubMed ID: 27411808
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
[TBL] [Abstract][Full Text] [Related]
20. Systemic-onset juvenile idiopathic arthritis and HLA-B27 juvenile-onset undifferentiated spondyloarthritis in the same patient.
Padula A; Cutro MS; Nigro A; D'Angelo S; Olivieri I
Clin Exp Rheumatol; 2013; 31(1):157-8. PubMed ID: 23295075
[No Abstract] [Full Text] [Related]
[Next] [New Search]
